Kinnov Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder
KINNOV Therapeutics has reached a key clinical milestone for treatment of Alcohol Use Disorder with a Phase 2 clinical study for its game changing drug KT-110. PARIS, FRANCE, June 9, 2022 /EINPresswire.com/ -- KINNOV Therapeutics (“Kinnov”) announces it …